english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2014 > The Prescrire Information Awards for 2014 > 2014 Information Awards

The Prescrire Awards for 2014

The Prescrire Information Awards for 2014

The Prescrire Information Awards for 2014

Palmarès de l'information

The Information Awards focus on
the information provided to Prescrire
by the pharmaceutical companies
whose products we examined
in the New Products section
of our French edition in 2014. 

Palme

          Honours List
               (in alphabetical order)
OUTSTANDING:
CTRS (Cell Therapies Research & Services), EG Labo, Lucane Pharma, Mayoly Spindler
FOLLOWED BY:
Arrow Génériques, Bioprojet Pharma, GlaxoSmithKline, Mylan, Novartis Vaccines and Diagnostics, SERB

Red Cards
(in alphabetical order)
Almirall, Bayer Healthcare, Biogen Idec, Bristol-Myers Squibb, Celgene, Genzyme (Groupe Sanofi), Gilead Sciences, Janssen-Cilag, Menarini, MSD, Novartis Pharma, Pfizer, Sanofi-Aventis

 

About the 2014 Information Awards
Prescrire's reviews are based on a thorough literature search. Pharmaceutical companies hold a wealth of information on the drugs they market or withdraw from the market. Prescrire requests such data (mainly clinical data, packaging, and administrative and regulatory information) so that we can compare or add them to information obtained from other sources.

As is the case with the other Prescrire Awards, the Information Awards are granted in total independence, free from any industry or institutional influence.

The rules governing the Prescrire Awards are available (in French) > HERE

Some companies are transparent, others uncooperative
On the whole pharmaceutical companies provide Prescrire with a lot of information, some new and some that we have obtained elsewhere. Certain companies respond to our requests in a timely manner and provide us with relevant, detailed documentation, including unpublished data. These companies are placed on the Honours List. The companies rated as "Outstanding" provided us with exhaustive and detailed data, without delay and sometimes without being asked.

Other drug companies fail to respond to some or all of our requests for information, or provide only limited data. Some of them delay their response, then fail to provide usable information. Others omit the most relevant data. "Red cards" are given to highlight persistent shortcomings in the provision of information by some drug companies.

Yet transparency is a sign of a responsible company, determined to make health care safer by withholding none of the data obtained during the evaluation of their drugs, including their limitations.

Whenever we examine a new drug or indication, the review is accompanied by one of four pictograms rating the transparency of the company concerned for their response to our request for information about their product.
Information approfondie   Information restreinte   Information minimale    Rétention d'information
> Prescrire's Information Ratings
 

©Prescrire February 2015

"The Prescrire Awards 2014" Prescrire Int 2015; 24 (158): 74-79. (pdf, free)